Skip to Content

Join the 'Non-Small Cell Lung Cancer' group to help and get support from people like you.

Non-Small Cell Lung Cancer News (Page 4)

Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC

Breath Test May Detect Signs of Lung Cancer: Study

Posted 28 Jan 2014 by

TUESDAY, Jan. 28, 2014 – A simple breath test might reveal if a person has early-stage lung cancer, according to a new study. Researchers tested the exhaled breath of people with suspicious lung lesions that were detected on CT scans. The breath was tested for levels of four cancer-specific substances, called "carbonyls." The breath samples were analyzed using a special device developed at the University of Louisville. Having elevated levels of three of the four carbonyls was predictive of lung cancer in 95 percent of patients, while having normal levels of these substances was predictive of a noncancerous growth in 80 percent of patients, the researchers found. Elevated carbonyl levels returned to normal after lung cancer patients had surgery to remove the cancer, according to the study, which was to be presented Tuesday at the Society of Thoracic Surgeons annual meeting in Orlando, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Diagnosis and Investigation

Gilotrif Approved for Late-Stage Lung Cancer

Posted 14 Jul 2013 by

FRIDAY, July 12 – The drug Gilotrif (afatinib) has been approved by the U.S. Food and Drug Administration to treat spreading cases of non-small cell lung cancer (NSCLC) caused by certain gene mutations, the agency said Friday. The treatment, given priority FDA review, was sanctioned for tumors that express certain epidermal growth factor receptor (EGFR) mutations, as detected by a newly approved diagnostic, the agency said in a news release. Lung cancer is the number one cause of cancer-related death in both men and women, the FDA said. The disease is likely to be diagnosed in some 228,190 people this year, and is predicted to kill about 159,480, the U.S. National Cancer Institute said. EGFR mutations are found in about 10 percent of NSCLC cases. Gilotrif is designed to block proteins that spur development of cancer cells, the FDA said. The drug was approved along with a companion ... Read more

Related support groups: Non-Small Cell Lung Cancer

New Drug May Help Fight Certain Advanced Lung Cancers

Posted 3 Jun 2013 by

MONDAY, June 3 – For patients struggling with a common and deadly form of lung cancer, adding the drug ganetespib to a standard chemotherapy drug may boost survival, new research suggests. The finding centers on a class of medications known as heat shock protein 90 (Hsp90) inhibitors, and it's the first time in more than 10 years that researchers have uncovered a better way to treat this group of patients. The findings were slated for presentation Monday in Chicago at the annual meeting of the American Society of Clinical Oncology. "This is the first randomized study to demonstrate therapeutic benefit with a heat shock protein inhibitor in patients with cancer," study lead author Dr. Suresh Ramalingam, a professor of medical oncology at the Winship Cancer Institute of Emory University, in Atlanta, said in an ASCO news release. The study focused on patients with a form of non-small cell ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

New Drug May Help Immune System Fight Cancer

Posted 16 May 2013 by

THURSDAY, May 16 – An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows. The drug binds to a protein called PD-L1 that sits on the surface of cancer cells and makes them invisible to the immune system, almost like a cloaking device. "That [the protein] allows the tumor cell to grow unchecked and cause harm to the patient," said study author Dr. Roy Herbst, chief of medical oncology at Yale University. But with the protein blocked, the immune system can see and destroy cancer cells. Of 140 patients in the pilot safety study, 29 (or 21 percent) initially saw significant tumor shrinkage after at least three months on the medication. Researchers say 26 patients have continued to respond over time, including some who have been on the drug for more than a year. One ... Read more

Related support groups: Cancer, Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer

Test Approved to Detect Faulty Lung Cancer Gene

Posted 16 May 2013 by

THURSDAY, May 16 – The U.S. Food and Drug Administration has approved a test designed to detect a faulty gene that's present in about 10 percent of cases of non-small cell lung cancer (NSCLC). The cobas EGFR Mutation Test, a companion diagnostic to the approved cancer drug Tarceva (erlotinib), detects a mutation in the epidermal growth factor receptor (EGFR) gene, the FDA said in a news release. Lung cancer is the leading cause of cancer-related death for both men and women, accounting for about 228,000 annual cases in the United States. Some 85 percent of lung cancers are NSCLC, the FDA said. In approving the new diagnostic, the FDA also sanctioned expanded use for Tarceva as a first-line treatment for people with NSCLC that has spread to other parts of the body and who have the mutated gene, the agency said. The new diagnostic is produced by California-based Roche Molecular Systems. ... Read more

Related support groups: Non-Small Cell Lung Cancer, Diagnosis and Investigation

Freezing Treatment May Help Destroy Lung Tumors: Study

Posted 15 Apr 2013 by

SUNDAY, April 14 – A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds. At least in the short-run – meaning three months after the procedure – the intervention known as "cryoablation" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest. However, some patients developed new tumors in that time period, the researchers noted. The study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease. Rather, they said that for certain patients who may not be eligible for more standard surgical approaches, the therapy has potential as an alternative means for offering an improved quality of life for a longer period of time. "'Promising' is the ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

Tofu-Rich Diet May Help Women With Lung Cancer Live Longer

Posted 26 Mar 2013 by

TUESDAY, March 26 – Eating tofu and other soy foods may help women who develop lung cancer increase their odds of living longer. A study of women from Shanghai, China, published in the March 25 issue of the Journal of Clinical Oncology, links high soy consumption before a lung cancer diagnosis with longer survival. "This is the first study to suggest an association between soy food consumption and lung cancer survival," said study author Dr. Gong Yang, a research associate professor of medicine in the division of epidemiology at Vanderbilt University Medical Center, in Nashville. Eating soy products in small amounts in the years preceding a lung cancer diagnosis didn't seem to pose a benefit, though. Lung cancer is the leading cause of death among women in the world. It forms in the tissues of the lungs, usually in the cells that line the air passageways. The five-year survival rate is ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Bronchogenic Carcinoma

FDA Approves Abraxane for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Posted 12 Oct 2012 by

SUMMIT, N.J.--(BUSINESS WIRE)--Oct 12, 2012 - Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. “Non-small cell is the most common type of lung cancer, the leading cause of cancer death in the United States,” said Dr. Mark A. Socinski, MD, Director, Lung Cancer Section, Division of Hematology/Oncology, University of Pittsburgh, and lead investigator of Abraxane phase II and phase III lung cancer trials. “The FDA approval of Abraxane is exciting for healthcare professionals because it offers an important new treatment option for all types of non-small cell lung ... Read more

Related support groups: Non-Small Cell Lung Cancer, Paclitaxel, Abraxane, Paclitaxel Protein-Bound

Abraxane Approved to Treat Advanced Lung Cancer

Posted 12 Oct 2012 by

FRIDAY, Oct. 12 – Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration – in combination with the drug carboplatin – to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday. Abraxane was first approved in 2005 to treat breast cancer. In a new clinical study of 1038 people, the most common adverse reactions to the drug were anemia, loss of hair, nausea, fatigue, loss of appetite, irregularity, rash and swelling. Abraxane is produced by Celgene Corp., based in Summit, N.J. More information To learn more about non-small cell lung cancer, visit the U.S. National Cancer Institute. Read more

Related support groups: Non-Small Cell Lung Cancer, Abraxane, Paclitaxel Protein-Bound

Targeted Radiation for Lung Cancer May Carry Risks

Posted 13 Jun 2012 by

WEDNESDAY, June 13 – A woman with early-stage lung cancer died recently after highly targeted radiation therapy zapped not just her tumor, but surrounding tissue, fatally damaging her airway. Though just a single case report of an apparently deadly complication, the authors warn that targeted radiation therapy – specifically, stereotactic body-radiation therapy – has inherent risks, even when done properly and using an even lower dose of radiation than is considered safe. Stereotactic body-radiation therapy focuses beams of radiation on a tumor in the hopes of killing it. Because it uses highly precise beams that can focus large doses of radiation with millimeter accuracy, the technique is considered an advance over older types of radiation therapy, which are generally more diffuse, explained Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society. The goal ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

Older Lung Cancer Patients Less Likely to Be Treated

Posted 4 May 2012 by

FRIDAY, May 4 – A study of seniors with non-small cell lung cancer found that older patients are less likely to receive treatment than younger patients, regardless of their overall health and prognosis. Non-small cell lung cancer is the most common type of lung cancer. For this study, U.S. researchers looked at data from more than 20,000 lung cancer patients aged 65 and older in the VA Central Cancer Registry between 2003 and 2008 and found that, for all stages of lung cancer, younger, sicker patients were more likely to receive treatment than otherwise healthy older patients. That may not be best for patients, the researchers said. Previous research has shown that older lung cancer patients who are otherwise healthy can benefit from treatment, while those with other illnesses are more vulnerable to the toxicity of cancer treatments. "It's clear that, as human beings and physicians, we ... Read more

Related support groups: Non-Small Cell Lung Cancer

Avastin No Benefit to Older Lung Cancer Patients: Study

Posted 17 Apr 2012 by

TUESDAY, April 17 – Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report. An earlier trial had found that Avastin (bevacizumab) did improve survival, but not in patients aged 65 and older. Even so, the researchers noted, most patients diagnosed with non-small cell lung cancer are 65 and older and Medicare still covers the cost of the drug. "A drug that we were just ecstatic about in 2006, we have to be more circumspect about," said lead researcher Dr. Deborah Schrag, an oncologist at Dana Farber, in Boston. Avastin should be used judiciously, she added, noting that "older patients should discuss it with their doctors, but we cannot say it provides a survival advantage based on these data." However, Schrag does not think Medicare ... Read more

Related support groups: Non-Small Cell Lung Cancer, Avastin, Bevacizumab

Lung Cancer Screening Might Pay Off, Analysis Shows

Posted 9 Apr 2012 by

MONDAY, April 9 – Screening people at high risk for lung cancer could be at least as cost-effective as screening for breast, colorectal and cervical cancers, a new study suggests. A group of actuaries specializing in the health care industry estimated how much private insurance companies would pay and the survival benefits that would follow if they covered lung cancer screening. They based their study on using a scanning technology called low-dose spiral computed tomography (CT) on people between the ages of 50 and 64 who were at high risk for developing lung cancer due to their smoking history. The authors estimated that screening high-risk people would cost providers less than $19,000 for every year of life saved. The study was published in the April issue of Health Affairs. In comparison, the costs per life-year saved for breast, colorectal and cervical cancer screening – the three ... Read more

Related support groups: Smoking, Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Diagnosis and Investigation, Computed Tomography

Early Study Finds Some Promise for Lung Cancer Vaccine

Posted 4 Apr 2012 by

WEDNESDAY, April 4 – A new therapeutic vaccine appears to lengthen the lives of patients with a certain type of lung cancer, according to results of a small phase 2 trial. The drug, belagenpumatucel-L (Lucanix), extended the lives of patients with nonprogressive non-small cell lung cancer and increased the five-year survival rate among some patients with moderately advanced cancer to 50 percent, researchers found. For the study, 75 patients with stage 2, 3A, 3B or 4 cancer were randomly assigned to various doses of the vaccine, which was derived from four lung cancer cell lines. Staging refers to the severity of cancer. A stage 3 cancer has spread nearby, while a stage 4 cancer has spread to another organ. Overall, the patients survived an average of 14.5 months and the five-year survival rate was 20 percent, lead researcher Dr. Lyudmila Bazhenova, an associate clinical professor at ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer

Immune-Based Drug Combo Might Extend Cancer Survival

Posted 2 Apr 2012 by

MONDAY, April 2 – Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don't get the combination. These new study findings, slated for presentation this week at the annual meeting of the American Association for Cancer Research in Chicago, were seen across individuals with many different forms of advanced malignancies, including breast, lung and colon cancers. Retinoic acid is derived from vitamin A. Interleukin-2, a compound that fortifies the immune system, is approved at high doses to treat "metastatic" melanoma and kidney cancer. Metastatic means that a cancer has spread. The study showed that "these biological compounds may work at low doses. Bigger doses are not always better," said lead author Dr. Francesco Recchia, director of the oncology department at Civilian Hospital in Avezzano, ... Read more

Related support groups: Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma, Pancreatic Cancer, Ovarian Cancer, Small Cell Lung Cancer, Melanoma - Metastatic, Gastric Cancer

Page 1 2 3 4 5 6 7 8 9 Next

Ask a Question

Further Information

Related Condition Support Groups

Lung Cancer

Related Drug Support Groups

methotrexate, Tarceva, Avastin, Taxol, Xalkori, cisplatin, Taxotere, cyclophosphamide, Gemzar, view more... paclitaxel, capecitabine, Iressa, gemcitabine, Opdivo, Alimta, Keytruda, erlotinib, docetaxel, gefitinib, Cyramza, Abraxane, bevacizumab, cetuximab, amifostine, Platinol, afatinib, ramucirumab, Gilotrif, Navelbine, Methotrexate LPF Sodium, pembrolizumab, crizotinib, vinorelbine, pemetrexed, Alecensa, Trexall, Tagrisso, nivolumab, alectinib, osimertinib, Portrazza, Zykadia, Ethyol, ceritinib, porfimer, paclitaxel protein-bound, necitumumab, Onxol, Platinol-AQ, Folex PFS, Photofrin, Docefrez